Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | STS | P08842 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218765 | 1.00 | LMNA (0.60) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738546 | 1.00 | LMNA (0.60) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738536 | 0.91 | LMNA (0.59) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216027 | 0.90 | LMNA (0.58) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216028 | 0.90 | LMNA (0.58) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL19226865 | 0.90 | LMNA (0.58) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738507 | 0.89 | LMNA (0.64) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL219285 | 0.89 | LMNA (0.64) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL10269454 | 0.89 | LMNA (0.64) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216878 | 0.89 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435973-B2 | 17-beta HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8288367-B2 | Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one | SOLVAY PHARMACEUTICALS GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-1888615-B1 | 17 -HSD1 AND STS INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8030298-B2 | 17β-HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2099814-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008065100-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1888615-A1 | 17 -HSD1 AND STS INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | SOLVAY PHARMACEUTICALS GMBH | 2006-12-14 | — | — | US | disclosed |
| WO-2006125800-A1 | 17β-HSD1 AND STS INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | HSD17B11, HSD17B1, HSD17B2 | LMNA 3172/4885HSD17B1 2/4885MAPT 2263/4885 |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | LMNA 2693/4885HSD17B1 2/4885MAPT 3025/4885 |
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | HSD17B11, HSD17B1, STS | LMNA 3667/4885HSD17B1 2/4885MAPT 3497/4885 |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | STS, HSD17B11, HSD17B1 | LMNA 3074/4885HSD17B1 3/4885MAPT 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.